Bringing a medical device to market in Brazil isn’t something you can approach casually. The country has a well established regulatory system built around ANVISA, a centralized agency that controls classification, registration, manufacturing quality, imports and post market activities.
As registration requirements for each device vary based on device classification and pathway, understanding the process is essential. This article will help you to get the understanding of the Medical Device Registration Process in a simplified manner.
Regulatory Authorities for Medical Devices in Brazil
There is no delegated authority at the state level for medical device registration in Brazil. ANVISA Agência Nacional de Vigilância Sanitária is the sole national authority. It controls the process from initial classification through post market monitoring.
ANVISA defines regulatory requirements through Resolutions of the Collegiate Board (RDCs), Normative Instructions (INs) and Supplementary guidance documents. The core instruments currently in force are RDC 751/2022 (classification and marketing authorization for medical devices), RDC 830/2023 (in vitro diagnostics) and RDC 848/2024 (essential safety and performance requirements), supported by Normative Instructions such as IN 283/2024 (conformity assessment standards) and IN 320/2024 (rules for grouping similar devices). These are the regulatory documents that define how documentation should be organized and what standards apply to manufacturing quality.
Customs clearance and import activities may involve additional governmental bodies. But registration decisions are finalized by ANVISA. Their ruling applies nationally and their SOLICITA portal is the submission platform manufacturers will use throughout the process.
For foreign manufacturers, this centralized structure means that a single regulatory strategy can be applied across the entire Brazilian market once registration requirements are met.
Brazil Medical Device Classification
Under RDC 751/2022, medical devices are grouped into four risk classes. The scale runs from Class I for lower-risk products to Class IV for devices associated with the highest level of risk.
| Class | Risk level | Instruments |
| Class I | Low |
Non sterile, non measuring
|
| Class II | Moderate |
Syringes, non-implantable monitoring equipments
|
| Class III | Higher |
Implantable and active devices
|
| Class IV | Highest |
Cardiac implants, device interacting with nervous system, critical products
|
ANVISA’s actual classification system runs on 22 detailed rules (Annex I of RDC 751/2022) based on factors like invasiveness, duration of contact, the nature of the patient population it’s designed for and whether the device is active. So above given device type can shift classes depending on those specifics.
If the intended use puts the device genuinely on the boundary between two classes, the manufacturer must request a formal ANVISA determination before proceeding.
Brazil Registration Pathways for Medical Devices
Once the risk class has been confirmed, the next question is which registration pathway applies. Two pre-market authorization pathways are available depending on the device classification.
Notification Process (Notificação) applies to Class I and Class II products. It’s less document intensive and typically moves faster through ANVISA’s review, but “simplified” doesn’t mean uncontrolled. Cadastro submissions still require a BRH, correct labeling, GMP compliance evidence and technical documentation aligned with ANVISA’s requirement.
Full registration is required for Class III and Class IV devices. The technical dossier is more lengthy, clinical and performance evidence is expected, GMP certification of the manufacturing site is mandatory and ANVISA’s technical review is more thorough.
BRH Requirements for Medical Devices
Foreign manufacturers cannot hold a Brazil medical device registration themselves. A Brazilian legal entity called Brazil Registration Holder (BRH) must be appointed. This requirement comes from Federal Law 6,360/1976 and is reinforced by ANVISA’s own guidance. It is not waivable.
BRH must hold a valid AFE issued by ANVISA and should be registered with a valid CNPJ (National Registry of Legal Entities). The AFE that the BRH must hold is governed under RDC 16/2014. Selecting the right BRH is often one of the most important decisions in the registration process. Once appointed, BRH takes on legal responsibility to ANVISA for the product
The BRH carries significant regulatory responsibilities which includes:
- Maintaining the technical documentation supporting the registration
- Managing complaint handling and adverse event reporting to ANVISA
- Coordinating field safety corrective actions when required
- Serving as the primary communication channel with ANVISA throughout the product’s commercial life
Medical Device Regulatory Guidelines in Brazil
ANVISA defines regulatory requirements through several regulatory documents.
RDC 751/2022 establishes the risk classification model and core documentation requirements. RDC 848/2024 introduces updates that manufacturers entering the market need to account for. Normative Instructions (INs) provide operational detail on specific obligations including labeling and vigilance reporting.
Technical Guidance Documents is the Informational guidance that reflects ANVISA’s evaluation approach.
Brazil also participates in Mercosur regulatory harmonization through its health-sector working group (SGT nº 11) and the associated Medical Devices Sub-commission. It does affect how some technical standards and common nomenclature systems are applied. But in the end Brazilian regulatory requirements remain independently applicable too.
Medical Device Registration Process in Brazil
The Brazil Medical Device Registration Process follows a defined sequence. It also forms the foundation of the broader Medical Device Approval Process in Brazil. Although the exact timeline varies by device type and risk class, most registrations move through the following sequence.
Step 1 : Confirmation Classification
Determine the applicable risk class under RDC 751/2022. Classification drives every downstream requirement such as registration route, documentation depth, GMP obligations and fees. Getting the classification right at the outset helps avoid unnecessary delays later in the process.
Step 2 : Appoint a Brazil Registration Holder (BRH)
Identify and formally appoint a locally incorporated Brazilian entity with a valid ANVISA AFE. Document the appointment through a written agreement included in the registration dossier.
Step 3 : Assess GMP Status
For Class III and IV devices, confirm whether the manufacturing site holds a current CBPF for the relevant product category. CBPF runs on its own timeline and cannot be shortened by technical file quality. Many manufacturers begin this assessment early because GMP readiness can influence the overall registration timeline.
Step 4 : Prepare Technical Documentation
Arrange the dossier under RDC 751/2022 requirements. Include device description, intended use, technical specifications, risk management documentation, clinical or performance evidence, biocompatibility data, software records where applicable, sterilization validation if relevant and Portuguese labeling and IFU.
Step 5 : Submit via SOLICITA
The BRH submits electronically through ANVISA’s SOLICITA platform with the applicable TFVS fee. Before submission, it is advisable to verify that all supporting documents are complete and consistent, as administrative deficiencies can lead to avoidable delays.
Step 6 : ANVISA Technical Review
Anvisa evaluates the submission. Requests for clarification are common, particularly for higher-risk products, so manufacturers should plan resources accordingly. Deficiency requests delay the timeline. Complete and timely responses are essential.
Step 7 : Registration Grant
On successful review and GMP confirmation, ANVISA publishes the registration in the Diário Oficial da União. For Class III and IV devices (Registro), the authorization is valid for ten years from the date of publication. Class I and II notifications (Notificação) have no fixed expiration and remain valid indefinitely unless cancelled.
Note that Steps 3, 6 and 7 as detailed above describe the fuller Registro pathway for Class III/IV devices. Class I/II devices follow the same basic skeleton but via the lighter, faster Notificação route, without the same GMP-confirmation gate or fixed-term expiration.
Required Documents for Medical Device Registration in Brazil
A Class I product and a Class IV implantable device carry very different documentation burdens. Having said that, irrespective of which class the device is, the documentation should be accurate and aligned with ANVISA’s requirements under RDC 751/2022.
Core documentation components typically include are:
- Device description and intended use
- Technical specifications and performance data
- Risk management documentation (aligned with ISO 14971)
- Clinical evaluation or performance evidence (required for higher risk devices)
- Biocompatibility data per ISO 10993 where patient contact exists
- Software documentation per IEC 62304 where applicable
- Sterilization validation records where the device is supplied sterile
- GMP certification (CBPF) for manufacturing site (required for Class III/IV)
- Labeling ad IFU in Brazilian Portuguese
- BRH authorization document and AFE confirmation
Foreign documents must be authenticated. For documents from Hague Apostille Convention member countries, authentication is done through an apostille. For documents from non-member countries, authentication is done through consularization (authentication through a Brazilian consulate/embassy).
ANVISA accepts documents directly if they are already in Portuguese, English, or Spanish. Documents in other languages must be officially translated into Portuguese by a sworn translator (tradutor juramentado).
QMS Requirements for Medical Devices in Brazil
Medical device manufacturers in Brazil must comply with the applicable Quality Management System (QMS) requirements. Formal, audited GMP/QMS certification (B-GMP/CBPF) is required only for Class III and IV manufacturers. Class I and II manufacturers must still comply with B-GMP (Brazilian Good Manufacturing Practices) requirements, but are not subject to the same certification requirement as part of device approval.
When reviewing a manufacturer’s quality system, ANVISA looks beyond product specifications alone. Particular attention is given to the following areas:
- Design and development control
- Risk management integration (aligned with applicable international standards)
- Production and process controls
- Complaint handling and adverse event reporting systems
- Corrective and preventive action (CAPA) processes
- Supplier controls and traceability
Even manufacturers already operating under ISO 13485 should review Brazilian requirements separately rather than assuming full equivalence.
Manufacturers holding current ISO 13485 certification can use it as general supporting evidence, but an MDSAP audit report specifically is what ANVISA accepts as a substitute for its own on-site GMP inspection. But it doesn’t substitute for ANVISA’s own GMP certification (CBPF) for Class III and IV devices.
For Class III/IV manufacturers, the fastest route to a CBPF is often through the Medical Device Single Audit Program (MDSAP). Since RDC 745/2022, ANVISA accepts a valid MDSAP audit report as substitute evidence for its own on-site inspection. CBPF certificates issued on this basis are valid for four years.
Manufacturers without MDSAP must undergo ANVISA’s direct inspection process, which has historically taken considerably longer.
GMP Requirements for Medical Devices in Brazil
Good Manufacturing Practice (GMP) requirements for medical devices in Brazil are defined under RDC No. 665/2022.
What gets assessed during the inspection is broad. Production control, Design controls, CAPA systems, supplier qualification processes, validation records and complaint handling infrastructure.
The Certificado de Boas Práticas de Fabricação (CBPF) is the official certification through which ANVISA formally confirms that a manufacturing site meets Brazilian GMP requirements. Certification timelines vary considerably depending on route. Manufacturers using an MDSAP audit report as substitute evidence for the on-site inspection typically see faster turnaround, while those relying on direct ANVISA inspection should expect a longer wait, as ANVISA prioritizes reviews.
CBPF is issued as per manufacturing site and is tied to the risk class/category of products covered, per RDC 687/2022’s certification criteria. A single manufacturing site may need multiple certificates if it produces devices across different ANVISA product categories.
For foreign manufactures, ANVISA may conduct on site inspections at facilities outside Brazil or recognize inspections conducted by other competent authorities under bilateral arrangements.
Medical Device Labeling & IFU Requirements in Brazil
Labeling compliance is an important part of Medical Device Registration in Brazil. Required label content typically includes:
- Device commercial name
- Manufacturer’s name and address
- BRH identification and Brazilian address (as locally responsible party)
- ANVISA registration number
- Lot or batch number
- Manufacturing date and expiration date where applicable
- Sterility indicators and sterilization method for sterile products
- Required safety warnings and precautions
The IFU must include intended use, target user and patient population, indications, contraindications, operating instructions, maintenance and storage requirements and applicable safety information. For certain low-risk devices where the label alone is sufficient to ensure safe use, a separate IFU document isn’t required. The label itself is uploaded in place of the IFU in ANVISA’s Documentary Repository of Medical Devices.
Portuguese language requirements are particularly important. All materials must be in Brazilian Portuguese. It should be reviewed and adapted to ensure terminology and phrasing are appropriate for the Brazilian healthcare context.
Registration Timelines for Medical Devices in Brazil
Timelines for Brazilian medical device registration vary depending on device class and submission quality.
The reality is that timelines vary considerably depending on:
- Device classification
- Regulatory route
- Submission quality
- ANVISA workload
- Additional information requests
For Notificação (Class I and Class II), review is much faster and largely administrative, since notification exempts devices from prior technical analysis. In practice, timeline ranges from 60 to 90 days.
Registro (Class III and IV), the process generally takes longer. Under Federal Law 13.411/2016, ANVISA has a maximum decision period of 180 to 365 days for standard-category registrations, which can be extended once by up to one-third of that period
This target applies where documentation is complete and accurate. ANVISA does not provide a single universal review timeline applicable to all medical devices. GMP certification adds a parallel timeline. If a manufacturing site doesn’t already hold a current CBPF, the process of obtaining one can take six months to over a year.
Artixio has observed that manufacturers who initiated GMP certification and technical dossier preparation simultaneously rather than sequentially tend to get to market faster than those who treat GMP as a downstream step.
Medical Device Registration Costs in Brazil
Medical device registration fees in Brazil are set through the TFVS. This tax was created by Law 9.782/1999 and is governed by RDC 222/2006.The fee amounts depend on the type of request, such as initial registration, notification, GMP certification, or renewal, and on the size and revenue of the applicant company.
Government fees represent one part. Additional costs may include BRH services, document legalization, translations, regulatory consulting support, GMP preparation activities and post approval maintenance requirements.
Separate GMP inspection fees apply for foreign manufacturing sites of Class III and IV devices, since these are the only classes subject to B-GMP or CBPF certification. This applies whether ANVISA conducts an on-site inspection directly or accepts a substitute MDSAP audit report. Even in the MDSAP route, ANVISA’s own B-GMP fee is still payable alongside the MDSAP auditing organization’s fee.
TFVS amounts are adjusted periodically and vary by exact petition type and company size. Manufacturers should confirm current fees directly against ANVISA’s published TFVS table, the annexes to RDC 857/2024, at the time of filing
Import Requirements for Medical Devices in Brazil
Commercial importation of medical devices into Brazil requires a valid ANVISA registration for each product being imported. Brazil Medical Device Import Registration requirements must be met before commercial shipments can enter the market.
Beyond registration status, the importing entity must hold an ANVISA Authorization to Operate (AFE) that specifically covers importation activities, for finished medical devices. As of December 2024, ANVISA clarified that importers of medical device components or parts are exempt from this AFE requirement, regardless of whether the component is for manufacturing a device in Brazil or for replacement purposes. The AFE itself is issued to Brazilian legal entities and must be maintained in current valid status.
Brazil’s import control system for medical devices operates through ANVISA’s surveillance mechanisms and the border Brazilian foreign trade administration system, which includes SISCOMEX (the integrated foreign trade system). Import licenses for medical devices are filed through the Portal Único Siscomex using a standardized LPCO document, and since mid-2025, TFVS fee payment for these import petitions is integrated directly into that same platform.
From a practical point of view the documentation alignment with registration should be reviewed before the first shipment leaves the manufacturing site. Documentation gaps discovered at the border tend to be more expensive to resolve.
Post Market Surveillance Requirements in Brazil
Post market obligations in Brazil are ongoing and governed primarily by RDC 67/2009 (technovigilance requirements), with IN 67/2019 adding further procedural detail. Obligations include:
- Adverse event reporting via NOTIVISA:
The most severe events, including deaths, serious threats to public health, and product falsification, must be reported within 72 hours of the responsible party becoming aware. Other adverse events that could become serious, along with certain occurrences reported abroad involving a product also registered in Brazil, must be reported within 10 days. Some technical complaints carry a 30-day deadline. These deadlines are set under RDC 67/2009. - Field Safety Corrective Actions (FSCAs):
The BRH coordinates recalls and safety communications in Brazil, executes required notifications to the distribution chain and reports to ANVISA according to defined procedures. - Complaint handling:
The BRH must maintain a functioning complaint management system that can evaluate and escalate device related complaints through the appropriate channels. - Labeling maintenance:
Post approval changes to labeling require ANVISA notification or approval depending on the nature of the change. - Registration renewal:
Registrations are valid for ten years. Renewal must be requested no earlier than 12 months and no later than 6 months before the registration’s expiration date as per RDC 250/2004. Missing this window results in ‘caducidade’ (lapse) of the registration, requiring a full new registration rather than a renewal.
The BRH must coordinate these actions in Brazil and notify ANVISA through the NOTIVISA reporting system.
Conclusion
Brazil rewards preparation. Manufacturers who understand Brazil Medical Device Registration Process early, get classification right, treat GMP as a priority from day one and choose a capable BRH consistently have better outcomes. The process is manageable when you know what you are dealing with.
If you need support with ANVISA regulatory requirements in Brazil or assessing your medical device registration process, our team can help you understand the requirements, identify potential challenges, and develop a practical regulatory strategy for market entry. Learn more about our Brazil regulatory services or reach out to the Artixio team at info@artixio.com.
FAQs
Q1 What is ANVISA Medical Device Registration?
ANVISA Medical Device registration is the regulatory authorization process required before medical devices can be marketed in Brazil. ANVISA reviews device information, safety data, intended use and applicable quality requirements before granting approval.
Q2 How does Brazil Medical Device Classification work?
Brazil uses a risk based classification system under RDC No. 751/2022. Device are classified into Class I, II, III or IV based on intended use, invasiveness, duration of contact and potential risk to patients.
Q3 Is a local representative required for Medical Device Registration in Brazil?
Yes, and this is not waivable. Foreign manufacturers must appoint a Brazilian legal entity, the Brazil Registration Holder (BRH), to act as the local registration holder before submitting applications to ANVISA.
Q4. What are the key Medical Device Regulatory Requirements in Brazil?
Major requirements include proper classification, ANVISA registration, BRH appointment, labeling compliance, quality management controls, GMP obligations where applicable, import compliance and post market surveillance activities.
